Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Elixir grants Novartis option on development programs

Executive Summary

Elixir Pharmaceuticals has granted Novartis AG an option to acquire development and commercialization rights to either its ghrelin agonist candidate (in-licensed in 2005 from Bristol-Myers Squibb) or one of its sirtuin (SIRT) programs.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)

Related Companies